21 Apr 09 Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity In Multiple Cancer Cell Lines

Allos Therapeutics, Inc. (Nasdaq:ALTH) announced new data demonstrating the anticancer activity of its investigational drug, pralatrexate, in colon, ovarian, lung, prostate, and head and neck cancer cell lines. The preclinical research further showed that the antiproliferative effects against these cancer lines were achieved at drug concentrations that are attainable in humans. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Denver, CO.

Related Posts:

Allos Therapeutics Completes Enrollment In Randomized Phase 2b Trial Of Pralatrexate In Patients With Advanced Non-Small Cell Lung Cancer Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the completion of patient...
Allos Therapeutics Announces U.S. Availability Of FOLOTYN™ (pralatrexate Injection) For Relapsed Or Refractory Peripheral T-Cell Lymphoma Allos Therapeutics, Inc. (Nasdaq:ALTH) announced that FOLOTYN™ (pralatrexate injection) is...
Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation For The Treatment Of Bladder Cancer Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the U.S. Food...
Allos Therapeutics Announces Final Results From Pivotal PROPEL Trial Of Pralatrexate In Patients With Peripheral T-cell Lymphoma Allos Therapeutics, Inc. (Nasdaq: ALTH) announced final results from the...
Allos Therapeutics’ FOLOTYN™ Shows Activity In A Dose Finding Phase 1 Study Of Relapsed Or Refractory Cutaneous T-Cell Lymphoma Allos Therapeutics, Inc. (NASDAQ: ALTH) announced updated data from its...
Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation For The Treatment Of Bladder Cancer By The European Commission Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the European Medicines...